졸업논문청구논문

R- 과 S- Etodolac의 거울상 이성질체의 (1R)-(-)-Menthyl Chloroformate의 유도체화를 통한 HPLC-FLD로 분리

Separation of R- and S- Etodolac Enantiomers by High Performance Liquid Chromatography - Florence Detector after Derivatization with (1R)-(-)-Menthyl Chloroformate

> 강 한 필 (**Kang, Hanpil**) 13003

과학영재학교 경기과학고등학교 2016 Separation of R- and S- Etodolac Enantiomers by High Performance Liquid Chromatography - Florence Detector after Derivatization with (1R)-(-)-Menthyl Chloroformate

> Advisor: Najin, Jeong by 13003 Kang, Hanpil Gyeonggi Science Highschool for the gifted

A thesis submitted to the Gyeonggi Science Highschool in partial fulfillment of the requirements for the graduation. The study was conducted in accordance with Code of Research Ethics¹.

2015. 6. 19. Approved by Teacher Jeong, Najin (sig-

nature)

[Thesis Advisor]

¹Declaration of Ethical Conduct in Research: I, as a graduate student of GSHS, hereby declare that I have not committed any acts that may damage the credibility of my research. These include, but are not limited to: falsification, thesis written by someone else, distortion of research findings or plagiarism. I affirm that my thesis contains honest conclusions based on my own careful research under the guidance of my thesis advisor.

Separation of R- and S- Etodolac Enantiomers by High Performance Liquid Chromatography -Florence Detector after Derivatization with (1R)-(-)-Menthyl Chloroformate

강 한 필

위 논문은 과학영재학교 경기과학고등학교 졸업논문으로 학위논문심사위원회에서 심사 통과하였음.

2015년 6월 19일

심사위원장 가 나 다(인) 심사위원 메 르 스(인) 심사위원 정 나 진(인)

Separation of R- and S- Etodolac Enantiomers by High Performance Liquid Chromatography -Florence Detector after Derivatization with (1R)-(-)-Menthyl Chloroformate

Hanpil Kang

Abstract

Etodolac, one of nonsteroidal anti-inflammatory drugs(NSAIDs) found in R/S- form are shown to be have different pharmacodynamic and pharmacokinetic properties. R- contreats Leukemia while S- treats the symptoms of pain and inflammation. In this research, (1R)-(-)-Menthyl Chloroformate was used to derivate R/S- Etodolac which reacts with the Carboxyl group in pyridine catalyst. High Performance Liquid Chromatography - Florence Detector (HPLC-FLD) is used to qualificate two enantiomers of Etodolac, resulting in a resolution over 1 in a standard and serum sample.

R- 과 S- Etodolac의 거울상 이성질체의 (1R)-(-)-Menthyl Chloroformate의 유도체화를 통한 HPLC-FLD로 분리

초 록

비스테로이드성 진통제(NSAIDs)의 일종인 에토돌락(Etodolac)의 두 광학이성질체는 약역학과 약물동태학적으로 다른 성질을 가진다. R-의 형태는 백혈병을 치료에 효과가 있고, S-의 형태는 진통소염 작용을 한다. 이 연구에서는 피리딘 촉매 하에서 (1R)-(-)-멘틸 클로로포메이트를 R/S- 에토돌락의 카르복실기와 반응 시킨다. 고성능 액체 크로마토그래피 – 형광 검출기(HPLC-FLD)가 두 광학 이성질체를 분리하는데 사용되었으며 해상도 1 이상으로 정성할 수 있다.

Contents

Ι	Experimental
	II.1 Chemicals and Reagents
	II.2 High-performance Liquid Chromatography - Florence Detector
	II.3 Ultra-performance liquid chromatography – Mass Detector
	II.4 Protocol
	II.5 In-vitro test
	II.6 In-vivo test for rats
ΙΙ	Results and Discussion
	III.1 UPLC-MS Data
	III.2 HPLC-FLD Data
	III.3 Protocol Optimization
	III.3.1 Pyridine Volume
	III.3.2 Sonication time
	III.4 In-vitro test
	III.5 In-vivo test for rats

List of Figures

1	Etodolac, (-)-MCF and their products	1
2	BPI chromatogram of Menthyl Chloroformate-derivatized Etodolac	
	product	5
3	Extract ion chromatogram of Menthyl Chloroformate-derivatized	
	Etodolac product, [M+H]=426.29	5
4	Mass fragment of peak at retention time 4.11 minute and 4.37 minute.	6
5	HPLC-FLD data of protocol	6
6	Pyridine Volume and Peak 1's ratio	7
7	Sonication time and Peak 1's ratio	7
8	Chromatogram of Filtrate	8
9	In vivo test result	8

Tier of Tables	List	of	Tab	les
----------------	------	----	-----	-----

I Introduction

Etodolac, one of the nonsteroidal anti-inflamatory drugs (NSAIDs) is widely used for treating rheumatic and inflammatory diseases. This drug is used in the form of a racemic mixture but the pharmacodynamic and pharmacokinetic properties of the two enantimoers are different. R- contreats Leukemia[1] while S- treats symptoms like pain and inflammation. Menthyl Chloroformate was widely used as a derivating secondary amine, but it also reacts with the carboxyl group when the catalyst pyridine exists. High Performance Liquid Chromatography – Florence Detector (HPLC-FLD) and Ultra Performance Liquid Chromatography – Mass spectrometry (UPLC-MS) are powerful machines which can quantify and qualify products. In this research, HPLC-FLD was used to detect products made by the derivatization of (1R)-(-)-Menthyl Chloroformate to Etodolac. To check the two isomers' structure, UPLC-MS was used.

Figure 1: Etodolac, (-)-MCF and their products.

II Experimental

II.1 Chemicals and Reagents

R/S-Etodolac was purchased from Tokyo Chemical Industry (Tokyo, Japan). (1R)-(-)-Menthyl Chloroformate, Pyridine, L-Proline was purchased from Sigma-Aldrich Chemie (St. Louis, USA). Acetonitrile (ACN) and Methanol (MeOH) were purchased from Avantor Performance Materials, Inc (USA). NaCl was purchased from Merck KGaA (Darmstadt, Germany).

II.2 High-performance Liquid Chromatography - Florence Detector

High-performance liquid chromatography (HPLC) is widely used in analytic chemistry to separate, identify or quantify each component in a mixture. Gemini C18 Column was used at a flow rate of 1.0mL/min at 25°C used with 86.5% MeOH, 13.5% 10mM Acetic Acid. Florence Detector was used at a wavelength of λ ex= 235 nm; λ em= 345 nm.

Chemstation Software was used for system control and data processing.

II.3 Ultra-performance liquid chromatography – Mass Detector

Ultra-performance liquid chromatography – Mass Spectrometer (UPLC-MS) is widely used in analytic chemistry to separate, identify or quantify each component in a mixture through mass detection. A mass spectrum is a plot of the ion signal as a function of the mass-to-charge ratio. Mass spectra are used to determine the elemental or isotopic signature of a sample, find the masses of particles and of molecules, and to elucidate the chemical structures of molecules, such as peptides and other chemical compounds. UPLC BEH C18 Column (2.1 x 50mm, 1.7um) was used at a flow rate of 0.3mL/min, at 45°C. Elution conditions can be seen in [Table 1]. MassLynx Software was used for system control and data processing.

II.4 Protocol

The protocol for this experiment was as follows. 50uL 50mM etodolac soluted in ACN was added to 50uL urine. The solution was vortexed for 3 seconds, and then 900uL of ACN was added. The solution was then vortexed for 3 minutes, and then centrifuged for 5 minutes at 13500 rounds per minute. Next, 950uL of the upper layer of the solution was moved to another vial and evaporated using gentle nitorgen stream at 40 °C After, 160uL 100mM MCF soluted in ACN, 15uL

Table 1: Elution Condition of UPLC-MS.

Time(min)	Water(0.1% Formic Acid)	Methanol (0.1% Formic Acid)
0	20	80
9	10	90
11	0	100
13	0	100
15	20	80
17	20	80

pyridine, 25uL ACN were all added to the residue, and it was sonicated for 10 inutes. To finalize derivatization, 160uL 100mM proline soluted in distilled water was added, and then vortexed for 3 minutes. After being vortesed, it was placed at room temperature for 20 minutes. 28.7 mg of NaCl was added for Liquid-Liquid Extraction and the organic layer was filtered to complete to the optimization process.

II.5 In-vitro test

S-etodolac binds well to Albumin than R-etodolac.[4] Etodolac enantiomers were attempted to be identified using the stereoselective binding difference of etodolac to albumin. Protocol follows. Add 100uL 50ppm Etodolac. Evaporate in 40'C in gentle nitrogen stream. Add 100uL 50ppm Albumin in pH 7.4 phosphate buffer. Albumin purification was done to separate unbound Etodolac. We used Vivaspin 500 to separate protein. Protocol follows. In Vivaspin 500 add 100uL diluted water and centrifuge in 10000g for 5 minute. Add 100uL albumin and Etodolac mixture and centrifuge in 10000g for 3 minute. Filter 50uL and add 100 uL buffer and centrifuge in 10000g for 5 minute. Repeat 4 times filtering 100uL and adding 100uL buffer and centrifuge in 100g for 5 minute. Transfer concentrate and collect filtrate.

II.6 In-vivo test for rats

C57BL/6 mouse (male; 7 w) serum was used for Chrial determination of etodolac. The weight of mouse was 20g. Concentration of S-(+)-etodolac is lower than R-(-)-etodolac when injected 20mg/kg from 0 through 70 hour.[2] Protocol follows. Add 10mg etodolac to 50uL ethanol and vortex for 20s. Add 300uL Tween

and vortex for 1 minute and sonicate for 1 minute. After centrifuging 3 seconds, add saline to $10 \rm mL$. Inject etodolac to mouse. $200 \rm uL$ was injected to C57 mouse when the weight was $20 \rm g$.

III Results and Discussion

III.1 UPLC-MS Data




Figure 2: BPI chromatogram of Menthyl Chloroformate-derivatized Etodolac product




Figure 3: Extract ion chromatogram of Menthyl Chloroformate-derivatized Etodolac product, [M+H]=426.29

In [Figure 4], the mass fragment of the peak at 4.11 and 4.37 are equal. This means they are not geometric isomers, but they appear at different peaks. The mass at 172.1 and 287.15 shows that they have the structure of an etodolac.[3] So it can concluded that they are derivated etodolac.

III.2 HPLC-FLD Data

In [Figure 5], two peaks appear at 13.115 and 14.196. Two are enantiomers of etodolac derivatized by Menthyl Chlroforomate. The first peak will be referred to as Peak 1, and the second, Peak 2.

III.3 Protocol Optimization

The Pyridine volume and sonication time was optimized in this experiment. Peak 2 reacted faster than Peak 1. Therefore, the ratio of Peak 1 was used to verify that the reaction was completed.




Figure 4: Mass fragment of peak at retention time 4.11 minute and 4.37 minute.




Figure 5: HPLC-FLD data of protocol

III.3.1 Pyridine Volume

In [Figure 6], 5uL and 25uL of pyridine volume were significant by t-test. Optimized value found to be the median of the pyridine volume, which was not

Pyridine Volume and Peak 1's ratio 52 oith 50 48 44 Fyridine Volume Pyridine volume

Figure 6: Pyridine Volume and Peak 1's ratio

significant, 15uL.

III.3.2 Sonication time




Figure 7: Sonication time and Peak 1's ratio

In [Figure 7], 3min and 5min of sonication time were significant by t-test. Optimized value found to be the first of the significant time, which was not significant, 10min.

III.4 In-vitro test




Figure 8: Chromatogram of Filtrate

The in vitro test failed beacuse both etodolac enantiomers were well binded with protein in a short time, so the results of in-vivo test were analyzed.

III.5 In-vivo test for rats




Figure 9: In vivo test result

In [Figure 9], 1 hour after injection, the peak area of Peak 1 is 0.4676, while the peak area of Peak 2 is 0.0694. S-etodolac binds faster[2] and Peak 2 has less peak area, which means that Peak 2 is S-etodolac and Peak 1 is R-etodolac.

References

- [1] Brocks, D. R., Jamali, F., J. Pharm. Sci. 1991, 80, 1058–1061.
- [2] Shi JM et al. / Aeta Pharmacol Sin 2004 Aug; 25 (8): 996-999
- [3] Clin Pharmacokinet. Joseph P. Boni, Joan M. Korth-Bradely, Lyette S. Richards, Soong T Chiang, David R. Hicks, Leslie Z. Benet. 2000 Dec, 39(6) 459-469
- $[4]\,$ Chang-Chuan Guo et al. / Journal of Pharmaceutical Analysis 2011;1(3):184-190